<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03908294</url>
  </required_header>
  <id_info>
    <org_study_id>JWGUHMED1-012</org_study_id>
    <nct_id>NCT03908294</nct_id>
  </id_info>
  <brief_title>Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents</brief_title>
  <official_title>Examination of Changes of Parameters of Glucose Metabolism and Liver Fibrosis Stadium by Acoustic Radiation Force Impulse-Imaging and Transient Elastography in Patients With Chronic Hepatitis C Under Antiviral Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis C infection is associated with changes of glucose metabolism end increased
      frequency of impaired glucose tolerance. This might be a additional risk factor for disease
      and fibrosis progression. The study aims to evaluate whether a therapy with direct-acting
      antiviral agents leading to a sustained virologic response directly impacts parameters
      reflecting glucose metabolism and fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis C infection is associated with changes of glucose metabolism end increased
      frequency of impaired glucose tolerance. It is well known that metabolic factors play an
      important role in fibrosis progression and steatohepatitis for example in non-alcoholic
      steatohepatitis (NASH). Accordingly changes in glucose metabolism in patients with chronic
      hepatitis C might directly impact disease and fibrosis progression. The study aims to
      evaluate whether a therapy with direct-acting antiviral agents leading to a sustained
      virologic response directly impacts parameters reflecting glucose metabolism and fibrosis.
      Follow-up examinations will determine the long-term metabolic changes of successful
      elimination of the virus by antiviral treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2018</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with changes in glucose metabolism measured by fasting glucose</measure>
    <time_frame>From baseline up to one year after end of treatment</time_frame>
    <description>rate of patients with normal fasting glucose (&lt;100mg/dl), prediabetes (glucose 100-125mg/d) and diabetes (&gt;126mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of patients with changes in glucose metabolism measured by Homeostasis Model Assessment-index (HOMA)</measure>
    <time_frame>From baseline up to one year after end of treatment</time_frame>
    <description>Homeostasis Model Assessment-index (HOMA) measures insulin resistance:
&lt;2,0 insulin resistance unlikely
2,0 - 2,5 insulin resistance possible
2,5 - 5,0 insulin resitance likely
&gt;5,0 proven insulin resitance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of patients with changes in glucose metabolism measured by HbA1c</measure>
    <time_frame>From baseline up to one year after end of treatment</time_frame>
    <description>rate of patients with normal HbA1c (&gt;6% Hb), prediabetes (6-6.4% Hb) and diabetes (&gt;6.5% Hb)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis 1</measure>
    <time_frame>From baseline up to one year after end of treatment</time_frame>
    <description>Evaluation of changes of parameters reflecting liver fibrosis: Fibroscan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis 2</measure>
    <time_frame>From baseline up to one year after end of treatment</time_frame>
    <description>Evaluation of changes of parameters reflecting liver fibrosis: ARFI</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">46</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <condition>Liver Fibrosis</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Chronic hepatitis C under antiviral treatment with DAA</arm_group_label>
    <description>Patients with chronic hepatitis C infection and planned DAA treatment are enrolled prospectively. Parameters of glucose metabolism and liver fibrosis are measured at baseline, during therapy and up to one year after end of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Lab tests, non-invasive fibrosis (Fibroscan/ARFI)</intervention_name>
    <description>Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.</description>
    <arm_group_label>Chronic hepatitis C under antiviral treatment with DAA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic hepatitis C infection with planned antiviral DAA treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with chronic hepatitis C infection and planned antiviral therapy with
             direct-acting antiviral agents

          2. Age 18-99

          3. Informed Consent

        Exclusion Criteria:

          1. Patients without legal capacity for informed consent

          2. alcohol intake ≥ 20 g/d (f) und 30 g/d (m) within one year of study screening

          3. Decompensated cirrhosis

          4. viral co-infection

          5. HIV infection

          6. Non-viral chronic liver disease

          7. Malignancy within 5 years before study screening except basalioma

          8. liver transplant recipients

          9. weight loss ≥10% within 3 months before study screening

         10. Changes of diabetic drug treatment, lipid lowering therapy oder vitamin E within three
             months before study screening.

         11. Intake of medication associated with hepatic steatosis (e.g. steroids, methotrexate,
             amiodarone, tamoxifen, valproat, flutamide, tetracyclins, cytostatics etc.)

         12. Bariatric surgery in personal history

         13. Clinically relevant congestive heart disease, cardiac arrythmia, valvular heart
             disease)

         14. Implanted cardiac pacemaker or defibrillator

         15. Patients during pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Tania Welzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prof.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 2, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Georg Dultz</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

